McKesson Q1 adj EPS $5.83, revenue $67.2B; raises FY2023 outlook to $23.95-$24.65

MCKESSON CORP

2023-Q1 EPS reported $5.26 revenue$67,154,000,000

Adjusted EPS $5.83 vs $5.56 (+5%); GAAP EPS $5.25 vs $3.09 (+70%).
Revenue $67.2B, up 7% YoY, driven by U.S. pharmaceutical and specialty distribution.
FY2023 adjusted EPS guidance raised to $23.95-$24.65 from $22.90-$23.60.
Core adjusted EPS growth (ex-COVID programs) forecasted at 10-15% for fiscal 2023.
Guidance includes COVID vaccine distribution contribution of $0.35-$0.45 and ancillary supplies/testing of $0.75-$0.95 per share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.